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Abstract
Hemophilia A (HA) is a bleeding disorder characterized by spontaneous and pro-
longed hemorrhage. The disease is caused by mutations in the coagulation factor
8 gene (F8) leading to factor VIII (FVIII) deficiency. Since FVIII is primarily produced in
endothelial cells (ECs) in a non-diseased human being, ECs hold great potential for
development as a cell therapy for HA. We showed that HA patient-specific induced
pluripotent stem cells (HA-iPSCs) could provide a renewable supply of ECs. The
HA-iPSC-derived ECs were transduced with lentiviral vectors to stably express the
functional B domain deleted F8 gene, the luciferase gene, and the enhanced green
fluorescent protein gene (GFP). When transplanted intramuscularly into neonatal and
adult immune deficient mice, the HA-iPSC-derived ECs were retained in the animals
for at least 10-16 weeks and maintained their expression of FVIII, GFP, and the endo-
thelial marker CD31, as demonstrated by bioluminescence imaging and immuno-
staining, respectively. When transplanted into HA mice, these transduced HA-iPSC-
derived ECs significantly reduced blood loss in a tail-clip bleeding test and produced
therapeutic plasma levels (11.2%-369.2%) of FVIII. Thus, our studies provide proof-
of-concept that HA-iPSC-derived ECs can serve as a factory to deliver FVIII for the
treatment of HA not only in adults but also in newborns.
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1 | INTRODUCTION
Hemophilia A (HA) is an X-linked recessive bleeding disorder that can
lead to disability and even death due to spontaneous or injury-caused
prolonged bleeding if untreated. The incidence of HA is 1 in 5000
male births. The cause of the disease is mutations in the F8 gene lead-
ing to deficiency of clotting factor VIII (FVIII). Current standard treat-
ment for HA is factor replacement by repeated infusions of
recombinant FVIII proteins. However, this treatment has multiple
challenges. Infusion of the FVIII protein can treat but not cure the dis-
ease. The frequent (2-3 times/week) and long-term intravenous infu-
sion of FVIII can be inconvenient and risky for infections. In addition,
this treatment is extremely costly: the median cost of treatment is
$98 334 a year and is a lifelong expense.1 Furthermore, bleeding epi-
sodes are still common even with factor replacement therapy due to
the fluctuation of the infused FVIII levels. Currently, no alternative
therapy for HA is clinically available.
Gene and cell therapies have great potential to treat HA because
if these therapies can increase plasma FVIII levels only to above 1%
to 5% of normal FVIII levels, spontaneous bleeding episodes can be
markedly reduced. A recent gene therapy clinical trial for HA showed
successfully that a single high dose of an adeno-associated virus
serotype 5 (AAV5) vector encoding a functional B-domain-deleted
human F8 (bddF8) normalized the plasma FVIII levels in six of seven
patients over a period of 1 year.2 However, about 28.8% to 35.6%
of HA patients carry AAV neutralizing antibody due to previous
exposure to AAV and thus are not suitable for AAV-based gene ther-
apy.3 Furthermore, new born babies and young children are not suit-
able for the AAV-based gene therapy because AAV do not integrate
into the host genome and thus AAV-mediated gene expression is
greatly diluted when new born babies and young children grow into
adults. Repeated application of AAV therapy is prohibited because
administration again could induce a deleterious immune response to
the viral capsids.4,5
Cell therapy is actively being studied as a potential alternative for
treatment of HA. Multiple cell types have been tested for the delivery
of FVIII in vivo with promising results. These include liver sinusoidal
endothelial cells (LSECs),6,7 blood outgrowth endothelial cells
(BOECs),8-10 skin fibroblasts,11 mesenchymal stem cells,12-16 and
hematopoietic stem cells.17-23 Moreover, cell-based therapy could be
administered repeatedly if needed without causing significant side
effects. However, major challenges remain for the development of a
successful HA cell therapy: (a) sufficient supply of the therapeutic cells
and (b) sustained engraftment of the therapeutic cells.
Since FVIII is primarily expressed and posttranslationally modified
in endothelial cells (ECs) in a non-diseased human being,24-26 ECs
could be preferable FVIII delivery vehicles to other cell types. LSECs
and BOECs are excellent natural EC sources, but their limited avail-
ability hinders their clinical applications. Induced pluripotent stem cells
(iPSCs) can be generated from any person and extensively expanded.
A number of groups including us have efficiently derived ECs from
human embryonic stem cells and iPSCs.27-30 Therefore, iPSCs can pro-
duce an ample source of autologous ECs.
Here, we investigated whether the ECs derived from HA patients'
iPSCs (HA-iPSCs) can be used as FVIII delivery vehicles for the treat-
ment of HA in animal models. In order to express FVIII in the HA-iPSC-
derived ECs (HA-iPSC-ECs), we transduced these ECs with lentiviral
vectors encoding a functional bddF8 gene. Since HA is a genetic disease,
a child born with the disease needs to be treated early in his life. There-
fore, we assessed the engraftment of the HA-iPSC-ECs at the neonatal
stage in comparison to the adult stage, an analysis not previously stud-
ied. Finally, we assessed the functionality of the human HA-iPSC-ECs in
attenuating hemophilia symptoms in mouse models of HA.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Two independent HA-iPSC lines, HA-iPSC1 and HA-iPSC2, derived
from independent HA patients were previously reported by a
co-author, Dr. Pan's group.31,32 The efficiency of reprogramming was
from 0.0006% to 0.0024%.32 These HA-iPSCs were maintained on
Matrigel (Corning, Corning, New York) coated 6-well plates in mTeSR1
medium (STEMCELL Technologies, Cambridge, Massachusetts) with
daily change of the medium. Colonies were passaged every 4-6 days
either by manual picking with a sterile 1 mL pipette tip or ReLeSR
(STEMCELL Technologies). The iPSC line derived from a healthy
human being, iPS(IMR90)-4,33 was purchased from WiCell Research
Institute (Madison, Wisconsin) and was maintained as previously
described.30 The karyotypes of the healthy iPSC line and the HA iPSC
lines were confirmed normal. Human LSECs freshly isolated and
cryopreserved were purchased from ScienCell Research Laboratories
and were used at passage 1 (Carlsbad, California), whereas human cor-
onary artery EC (HCAEC), human cardiac microvascular endothelial cell
(HMVECs), and human umbilical vein EC (HUVEC) were purchased
from Lonza (Walkersville, Maryland). These primary ECs were cultured
in EC growth medium ECGM-MV2 (Promocell, Heidelberg, Germany).
Significance statement
The present study demonstrated that induced pluripotent
stem cells (iPSCs) derived from hemophilia A (HA) patients
can provide an ample supply of endothelial cells (ECs). The
HA-iPSC-derived ECs can be genetically modified to pro-
duce functional factor VIII. The relatively stable engraftment
of these ECs, in both neonatal and adult animals, and the
functional correction or alleviation of hemophilia by these
ECs in animal models, as shown in the study, provide the
basis for potential therapeutic development of HA-iPSC-
derived ECs for treating HA. The current study is a signifi-
cant step forward in development of autologous gene-
modified cell therapy for HA.
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2.2 | EC differentiation and transduction
ECs were differentiated from HA-iPSCs as previously described by our
laboratory.30 The cells on day 4 of differentiation were dissociated from
the culture plates with Accutase (Innovative Cell Technologies Inc).
These cells were transduced with lentiviral vector pMNDU3-LUC-PGK-
eGFP-WPRE encoding luciferase (LUC) and enhanced green fluorescent
protein (GFP) and pMNDU3-F8-PGK-NEO-WPRE34 encoding the B
domain deleted F8 (bddF8) and neomycin resistance gene (NEO) at mul-
tiplicity of infection (MOI) range from 1:4 to 1:8 for each vector. The
ECs were incubated in a small volume (0.5-1 mL) of ECGM-MV2
medium supplemented with 5 μg/mL polybrene (EMD Millipore, Bur-
lington, Massachusetts) for 20 minutes and then plated onto p100 cul-
ture dishes in 6 mL of the same medium. Media was changed to
ECGM-MV2 plus additional 50 ng/mL of vascular endothelial growth
factor (VEGF) the following day, and every 2 days after that. Cells were
harvested at days 7-9.
2.3 | Flow cytometry
The transduced cells were dissociated from the culture plates with
Accutase (Innovative Cell Technologies Inc) and washed with
phosphate-buffered saline (PBS). Following filtration through a 70-μm
nylon mesh (ThermoFisher Scientific, Waltham, Massachusetts), these
cells were subjected to flow cytometry analysis using a Beckman
Coulter Cytomics FC 500 (Beckman Coulter, Indianapolis, Indiana).
2.4 | Animal models and cell transplantation
The Institutional Animal Care and Use Committee at the University of
California, Davis, approved all animal experiments in the current study.
Immune-deficient NOD/SCID/IL2Rγ−/− (NSG) mice were purchased
from the vivarium of University of California, Davis. The HA-iPSC-
derived ECs that had been transduced to expressed bddF8, LUC, and
EGFP (1 × 106cells/mouse) were suspended in 40 μL of ECGM-MV2
medium and 10 μL of Matrigel and intramuscularly injected into the left
hind limb of adult NSG mice at 8-12 weeks old (mouse number n = 6).
Neonatal NSG mice at 4-7 days old were injected intramuscularly with
the transduced ECs (3 × 105cells/mouse) derived from HA-iPSC1
(mouse number n = 7) or HA-iPSC2 (mouse number n = 6) in 20 μL of
ECGM-MV2 medium and 5 μL of Matrigel into their left hind limbs.
C57BL/6 mice and HA mouse line B6;129S-F8tm1Kaz\J (B6F8)
carrying a F8 null mutation were purchased from The Jackson Labora-
tory in Sacramento, California. These hemophilia B6F8 mice were
immune-competent. To repress their immune system, adult B6F8 mice
at 8- to 16-week-old were mated and cyclosporine A was given to the
dam and sir in drinking water at 210 mg/L from the time that mating
pairs were set up to the pups were sacrificed. The transduced
HA-iPSC-EC/F8 (2-3 × 106cells/mouse) were transplanted into the
neonatal HA mice at 10 days old (mouse number n = 5) as described
above.
To generate an immune-deficient HA mouse strain to facilitate
human cell engraftment, we bred a female B6;129S-F8tm1Kaz/J mouse
to a male immune-deficient mouse, B6;129S-RAG2tm1Fwa CD47tm1Fpl
IL2rgtm1Wjl/J (BRG) (The Jackson Laboratory). The F1 progeny were
bred back to BRG mice. The progeny was crossed to each other for
three more generations. Both female and male mice with the RAG2
IL2rg F8 null (F8RG) were obtained. CD47 was either wild-type
(WT) or heterozygous in these mice. The transduced HA-iPSC-EC/F8
(1 × 107cells/mouse) in 300 μL of culture medium supplemented with
30% Matrigel were injected subcutaneously into the adult F8RG mice
(mouse number n = 7) as described above.
2.5 | Bioluminescence imaging
Luciferase substrate D-luciferin (Gold Biotechnology, St. Louis, Mis-
souri) was injected intraperitoneally or subcutaneously into the ani-
mals at 150-200 mg/kg weight. Five minutes later, the mice were
anesthetized using 2%-3% isoflurane (Piramal Critical Care, Bethle-
hem, Pennsylvania) for 5 minutes and then imaged with the IVIS Spec-
trum (PerkinElmer, Richmond, California) at the Genomic and
Molecular Imaging Center (Davis, California) under anesthesia up to
5 minutes. Animals were imaged at the day of cell transplantation and
weekly thereafter. The bioluminescence signal was presented as total
photons of the region of interest in 5 minutes of acquisition.
2.6 | Immunostaining
The mouse limb muscles with bioluminescence signal were dissected
and frozen in O.C.T compound (Sakura Finetek USA, Torrance, Califor-
nia) on dry ice and then placed into the −80C freezer for a minimum
of 24 hours. The tissue was then sectioned using a Cryotome FSE
(Thermo Scientific, Waltham, Massachusetts) set to 10–15 μm. Immu-
nostaining was performed as we previously described.35 The goat anti-
GFP antibodies or rabbit anti-GFP antibodies (Novus Biologicals,
Littleton, Colorado), rabbit anti-human CD31 antibodies (Bethyl Labora-
tories, Montgomery, Texas), and sheep anti-FVIII antibodies (Affinity
Biologicals, Ancaster, Canada) were diluted in PBS with 1% bovine
serum albumin (BSA) to 100, 200, and 50 folds, respectively. Secondary
antibodies including donkey anti-goat IgG conjugated with AlexaFluor
488 (ThermoFisher Scientific), donkey anti-rabbit IgG conjugated with
AlexaFluor 594 (ThermoFisher Scientific), and donkey anti-sheep IgG
conjugated with AlexaFluor 647 (EMDMillipore, Burlington, Massachu-
setts) were diluted to 500 folds in PBS with 1% BSA, respectively. Fluo-
rescence images were captured using a Nikon Eclipse Ti-U Inverted or
Nikon C2 microscope (Nikon Instruments Inc, Melville, New York).
2.7 | Quantitative PCR and RT-PCR
Gene expression was measured by quantitative reverse transcription
polymerase chain reaction (qRT-PCR) as we previously described.30
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The primers for VEGFR2, VE-cadnerin, and NOS3 have been previously
described.30 The primers for F8 are the following: 50-TCGAG
CAATAATTGGAGGGT-30 and 50-GTGGCAGACTTATCGAGGAAA-30.
The PCR products of human F8 from animal tissues were analyzed by
electrophoresis in a 2.5% agarose gel. For each condition, four to six
independent samples were assessed. The genomic DNA was isolated
from the transduced cells as previously described.35 The viral copy
number in the transduced cells was assessed by quantitative PCR as
previously described.36 Standard curve for viral sequence WPRE and
human VEGF was generated separately using a VEGF-coding lentiviral
vector as previously described.36 The copy number of WPRE and VEGF
in a DNA sample was calculated according to the respective standard
curve. The average copy number of viral inserts per cell was calculated
by dividing the number of WPRE by the number of VEGF and
then multiplying by 2, considering that each cell carries two copies
of VEGF.
2.8 | Tail clip assay for bleeding and blood
collection
A tail-clip assay was performed to determine the blood loss of the
transplanted HA mice compared with non-transplanted HA mice.
Mice were anesthetized using 2%-3% isoflurane. The mouse tail was
clipped at 1.5 cm from the tip. Blood was allowed to flow freely for
5 minutes before applying pressure on the cutting site for 1 minute
using a hemostat. Blood was collected into EDTA-coated tubes for a
total of 45 minutes after the cut and weighed. Animals were
sacrificed, and tissue at the injection site of the hind limb was col-
lected for RNA isolation. Blood was also collected directly from animal
hearts into tubes with citric acid. Mouse plasma was obtained after
centrifuging the blood for 5-10 minutes at 3300 rcf.
2.9 | Enzyme linked immunosorbent assay for
FVIII
A FVIII antigen enzyme linked immunosorbent assay (ELISA) kit
(Affinity Biologicals, Ancaster, Canada) was used to quantify the level
of human FVIII in the culture media and mouse plasma according to
the manufacturer's instructions with minor modifications. The capture
antibody specific for human FVIII was first coated onto the wells of
the provided microplate strips for 1 hour at room temperature or
overnight at 4C. Human pooled reference plasma standards, col-
lected culture media, and diluted mouse plasma samples were pip-
etted into the coated wells and incubated for 1 hour at room
temperature or overnight at 4C. Wells were washed with the wash
buffer, and a detection antibody was added and incubated for
1-2 hours. Following wash with the wash buffer, a substrate was
added and the color intensity was read at 450 nm with a SpectraMax
i3x plate reader (Molecular Devices, San Jose, California). Unknown
samples were compared with the standard curve and concentrations
estimated by extrapolation.
2.10 | Data representation and statistical analysis
Data is presented as average ± standard deviation. Each group had
four to six samples. Student's t test or Mann-Whitney U test was per-
formed to detect statistical difference between two testing groups.
One-way analysis of variance was performed to detect statistical dif-
ference between more than two testing groups.
3 | RESULTS
3.1 | Differentiation of ECs from HA-iPSCs
HA-iPSC1 and HA-iPSC2 were derived independently from different
HA patients and were previously characterized.31,32 We further veri-
fied the presence of pluripotency marker, octamer-binding transcrip-
tion factor 4, and the absence of EC marker, cluster of differentiation
31 (CD31), in these HA-iPSC lines using immunostaining (Figure 1A
and data not shown). We differentiated these two lines of HA-iPSCs
into ECs using our previously established protocol.30 Immunostaining
of the differentiated cells showed that CD31 was expressed on their
cell surfaces (Figure 1B). Quantitative RT-PCR assessment of the ECs
derived from HA-iPSC1 (HA-iPSC1-EC and HA-iPSC2 (HA-iPSC2-ECs)
for their expression of endothelial markers revealed that the ECs
derived from both HA-iPSC lines expressed VEGFR2 at the levels com-
parable to the ECs derived from non-diseased iPSCs (iPSC-ECs) as well
as primary liver sinusoidal ECs (LSECs) from a person not suffering
from HA (Figure 1C). The ECs derived from both HA-iPSC lines
expressed VE-cadherin and NOS3 at the level around 50% to 80% of
those in the iPSC-ECs, respectively (Figure 1C). The cause of the dif-
ferent expression level of VE-cadherin and NOS3 in the ECs derived
from different iPSC lines is not known. LSECs and HMVECs have been
previously shown to produce FVIII,26,37 whereas HCAEC and HUVEC
have not been shown to produce a detectable level of FVIII. Next, we
compared the level of the F8 mRNA in the ECs derived from non-
diseased iPSCs or HA-iPSCs with that in different primary ECs. We
found that the iPSC-ECs did express F8 mRNA at a level slightly higher
than that in HMVECs and markedly higher than that in HCAECs or
HUVECs (Figure 1D). However, the level of F8 mRNA in LSECs was
about 80-fold higher than that in the iPSC-ECs and even higher than
all other primary ECs tested (Figure 1D). Our data further prove the
previous observation that the level of FVIII expression varies markedly
among ECs from different tissues, and LSECs have the highest capacity
of FVIII production among these ECs. As expected, the ECs derived
from both HA-iPSC lines did not express F8 (Figure 1D).
3.2 | Ectopic expression of a functional
B-domain deleted F8 (bddF8), luciferase, and GFP
in HA-iPSC-derived ECs
To express a functional F8 gene in the HA-iPSC-ECs and to facilitate
quantitative assessment of the engraftment of these cells over time, we
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transduced HA-iPSC-ECs with a lentiviral vector pMNDU3-F8-PGK-
NEO-WPRE encoding bddF8 and NEO and a lentiviral vector
pMNDU3-LUC-PGK-eGFP-WPRE encoding the luciferase gene and
enhanced GFP.34 The transduced cells expressed GFP as detected
under a fluorescent microscope, and flow cytometry analysis of the
transduced cells showed that 91.3% of the cells were GFP-positive
(Figure 2A, B). The average copy number of the viral integration per cell
was 4.7 when the cells were transduced at MOI 8. The expression of F8
mRNA in these ECs was detected at the level of approximately threefold
higher than that in LSECs by qRT-PCR (Figure 2C). Furthermore, the
F IGURE 1 Characterization of HA-iPSCs and the ECs derived from these HA-iPSCs. A, Immunostaining image of HA-iPSC1 and HA-iPSC2
for OCT4 (red) and DAPI (blue). Scale bar = 50 μm. B, Phase (upper) and immunostaining image (lower) of HA-iPSCs and ECs derived from two
HA-iPSC lines as indicated for CD31 (red) and DAPI (blue). Scale bar=50 μm. C and D, qRT-PCR analysis of the expression of endothelial cell
markers (C) and F8 (D) as indicated in the ECs derived from iPSC, HA-iPSC1, HA-iPSC2, and human primary ECs including LSECs, HCAEC,
HMVEC, and HUVEC. **P < .01, ****P < .0001 vs iPSC-EC. ECs, endothelial cells; HA, hemophilia A; HCAEC, human coronary artery EC; HMVEC,
human cardiac microvascular endothelial cell; HUVEC, human umbilical vein EC; iPSC, induced pluripotent stem cell; LSECs, liver sinusoidal
endothelial cells; qRT-PCR, quantitative reverse transcription polymerase chain reaction
690 ROSE ET AL.
transduced ECs were capable of secreting FVIII as detected by ELISA
(Figure 2D). Apparently, the higher level of the F8 mRNA in HA-iPSC-
ECs in comparison to those in LSECs did not result in a significant higher
level of the secreted FVIII from HA-iPSC-ECs compared with that from
LSECs. The reason for this apparent inconsistency could be due to dif-
ferences in translation efficiency, protein stability, or efficiency in secre-
tion of FVIII between the HA-iPSC-ECs and LSECs. Our data show that
HA-iPSC-ECs can be transduced at a high efficiency to produce func-
tional FVIII proteins at a level no less than that in LSECs. These trans-
duced ECs are referred as HA-iPSC-ECs/F8 in the following sections.
3.3 | Sustained engraftment of HA-iPSC-ECs/F8
in neonatal and adult immune-deficient mice
To evaluate whether HA-iPSC-ECs/F8 can engraft stably in vivo, we
first transplanted these cells intramuscularly into adult immune-
deficient NSG mice. Each mouse received 1 × 106 cells. We assessed
the engraftment of HA-iPSC1-ECs/F8 in these animals over time
using an IVIS spectrum to detect the bioluminescence signal gener-
ated by the luciferase in the HA-iPSC1-ECs/F8. Bioluminescence
imaging demonstrated that the HA-iPSC1-ECs/F8 were retained in
these animal for 10 weeks after cell transplantation (Figure 3A, B),
when this experiment ended. Quantitation of the bioluminescence
signals in these mice revealed that there was a dramatic reduction of
the bioluminescence signals in the first 2 weeks following cell trans-
plantation and the remaining bioluminescence signals was stably
retained thereafter (Figure 3B).
Since HA is a genetic disease, the earlier a treatment is given,
the greater benefit a patient will receive. The rapid growth of a new-
born to an adult could promote either expansion or turnover of the
transplanted cells. To assess whether HA-iPSC-ECs/F8 can be
retained when transplanted at neonatal stage, we next subcutane-
ously transplanted HA-iPSC-ECs/F8 into neonatal NSG mice. Each
neonatal mouse received 3 × 105 ECs derived from either HA-iPSC1
or HA-iPSC2 line. Bioluminescence imaging of these mice over time
demonstrated that bioluminescence signals were retained for at least
16 weeks (Figure 3C, D), when the experiment ended. Again, the most
drastic reduction of the bioluminescence signals occurred in the first
2 weeks after cell transplantation. The cells survived the first 2 weeks
after being transplanted were able to persist to adult hood (Figure 3C,
D). The ECs derived from HA-iPSC1 line showed a slightly higher level
of engraftment compared with the ECs derived from HA-iPSC2 line
(Figure 3D).
To assess whether the HA-iPSC-ECs/F8 maintained their expres-
sion of F8 as well as the endothelial marker CD31 in vivo, we dis-
sected the limb tissue with bioluminescence signal from the mice
16 weeks after being transplanted with HA-iPSC1-ECs/F8 at the neo-
natal stage. The tissue sections were immunostained with GFP,
human CD31, and human FVIII antibodies. As a result, multiple clus-
ters of GFP-positive cells were detected in the tissue (Figure 4).
Importantly, these GFP-positive cells also expressed human FVIII and
human CD31 (Figure 4). Thus, our data suggest that HA-iPSC-derived
ECs can engraft in vivo for a relatively long time when transplanted
not only in adult but also in neonatal mice, and these ECs can maintain
their capability of producing FVIII in vivo.
F IGURE 2 The transduced HA-iPSC-
ECs expressed GFP and F8. HA-iPSC-ECs
were transduced with the lentiviral
vectors encoding bddF8, LUC and the
enhance GFP. Two-three days after the
transduction, the cells were assessed by
microscopy for GFP fluorescence (A)
(scale bar = 50 μm), and cytometry for
GFP-positive cells (B). C, qRT-PCR
analysis of the expression of F8 in the
transduced HA-iPSC-ECs/F8 and LSECs.
*P < .05. D, ELISA analysis of FVIII level in
the media collected from HA-iPSC-ECs or
LSECs in 72 hours using pooled human
reference plasma as standards. No
statistically significant difference was
detected. ECs, endothelial cells; ELISA,
enzyme linked immunosorbent assay;
FVIII, factor VIII; GFP, green fluorescent
protein; HA, hemophilia A; iPSC, induced
pluripotent stem cell; qRT-PCR,
quantitative reverse transcription
polymerase chain reaction
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3.4 | HA-iPSC-ECs/F8 reduced blood loss
in a mouse model of HA
To assess the functional effect of HA-iPSC-ECs/F8 in treating HA, we
purchased a F8 knock-out mouse strain B6;129S-F8tm1Kaz/J (B6F8)
from The Jackson Laboratory. This B6F8 mouse strain is immune-
competent. To allow human cell engraftment, we suppressed the
immune system in neonatal hemophilia mice by administration of
cyclosporine A at 210 mg/L in drinking water38 to the dam from the
day of mating to the end of the experiment. Lactational transfer of
F IGURE 3 Evaluation of the engraftment of HA-iPSC-EC/F8 in NSG mice. A, Bioluminescent images of the adult NSG mice transplanted with
HA-iPSC1-EC/F8 at the indicated weeks after the transplantation. B, Bioluminescent signal intensity for the mice in (A) over time (n = 6).
C, Bioluminescent images of the NSG mice transplanted with HA-iPSC1-EC/F8 at the neonatal stage. Images were taken at the indicated weeks
after the transplantation. D, Bioluminescent signal intensity for the mice transplanted with HA-iPSC1-EC/F8 (n = 7) or HA-iPSC2-EC/F8 (n = 4) at
neonatal stage over time. No statistically significant difference was detected between these two mouse groups transplanted with the ECs derived
from different HA-iPSC lines. ECs, endothelial cells; HA, hemophilia A; iPSC, induced pluripotent stem cell; NSG, NOD/SCID/IL2Rγ−/−
F IGURE 4 Histological analysis of the transplanted HA-iPSC1-EC/F8 in NSG mice. Neonatal NSG mice were transplanted with
HA-iPSC1-EC/F8 at their left hind limb. Sixteen weeks after the transplantation, a limb tissue with bioluminescence signal was immunostained
with antibodies against GFP, human CD31, and human FVIII. Fluorescence images for GFP (green), human CD31 (red), and human FVIII (white)
and the merge image of all three were shown. Nuclei were shown in blue (DAPI stain). Scale bar = 100 μm. ECs, endothelial cells; FVIII, factor VIII;
GFP, green fluorescent protein; HA, hemophilia A; iPSC, induced pluripotent stem cell; NSG, NOD/SCID/IL2Rγ−/−
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cyclosporine to nursing pups has been previously demonstrated.39
We transplanted HA-iPSC1-ECs/F8 intramuscularly into the hind limb
of the neonatal hemophilia B6F8 mice. Each mouse received 2 to
3 million cells. We detected bioluminescence signals in these mice
(Figure 5A) at 1 week after the transplantation, suggesting the reten-
tion of the transplanted cells. Next, a tail-clip bleeding test was per-
formed to evaluate the blood loss in these mice as well as the control
age-matched B6F8 mice and the control WT C57BL/6 mice
(WT mice). We found that the blood loss in the HA mice transplanted
with HA-iPSC1-ECs/F8 was significantly reduced compared with that
in the control HA mice (Figure 5B), and only slightly more compared
with that in the WT mice (Figure 5B). Although no F8 expression was
detected in the control B6F8 mice by qRT-PCR, the expression of F8
was detected in the mice transplanted with HA-iPSC1-ECs/F8
(Figure 5C). Therefore, our data demonstrated that transplantation of
HA-iPSC1-ECs/F8 is effective in delivering FVIII and attenuating the
symptom of HA.
3.5 | HA-iPSC-ECs/F8 produced therapeutic levels
of FVIII in an immune-deficient HA mouse model
Our preceding study showed that HA-iPSC1-ECs/F8 were retained in
immune-competent HA neonatal mice treated with cyclosporine A for
1 week. However, we found that the immune suppression by cyclo-
sporine A through milk might not be sufficient, because we could not
detect bioluminescence signal in those mice 2 weeks after the cell
transplantation. This is in contrast with our data using immune-
deficient NSG mice, which showed persistent bioluminescence signal
from the transplanted cells over 10-16 weeks (Figure 3). To facilitate
human cell engraftment, we generated an immune-deficient HA
mouse strain by breeding a female B6;129S-F8tm1Kaz/J mouse to a
male immune-deficient mouse, B6;129S-RAG2tm1Fwa CD47tm1Fpl
IL2rgtm1Wjl/J (BRG) (The Jackson Laboratory) and breeding their prog-
eny. The mice with F8 null RAG2 null IL2rg null genotype were
obtained and referred as F8RG mice.
F IGURE 5 Evaluation of the effect of HA-iPSC-ECs/F8 on blood
loss in B6F8 HA mice. Neonatal B6F8 HA mice were transplanted
with HA-iPSC1-EC/F8 and analyzed 1 week after the
transplantation. A, A representative bioluminescent image of the
mice. B, Blood loss in non-transplanted B6F8 mice or HA-iPSC1-EC/
F8-transplanted B6F8 mice and wild-type C57BL6 (WT) mice in a tail-
clip assay. (n = 4-5) *P < .05. C, The F8 mRNA in non-transplanted and
HA-iPSC1-EC/F8 transplanted HA mice as detected by qRT-PCR and
agarose gel electrophoresis. ECs, endothelial cells; HA, hemophilia A;
iPSC, induced pluripotent stem cell; qRT-PCR, quantitative reverse
transcription polymerase chain reaction
F IGURE 6 Evaluation of HA-iPSC-ECs/F8 in immune deficient
F8RG mouse model. Adult F8RG mice were subcutaneously
transplanted with HA-iPSC1-EC/F8 at their hind limbs and were
analyzed 2 weeks after the transplantation. A, A transplanted cell-
Matrigel plug at the transplantation site. B, Immunostaining of a
transplanted cell-Matrigel plug retrieved from the mice for GFP
(green), human FVIII (red), and DAPI (blue). Scale bar = 100 μm.
C, Plasma FVIII levels in non-transplanted and transplanted F8RG
mice were assayed by FVIII antigen ELISA (n = 7). *P = .015. ECs,
endothelial cells; ELISA, enzyme linked immunosorbent assay; FVIII,
factor VIII; GFP, green fluorescent protein; HA, hemophilia A; iPSC,
induced pluripotent stem cell
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We transplanted HA-iPSC1-ECs/F8 subcutaneously into the hind
limb of the adult F8RG mice. Each mouse received 10 million cells. We
estimated that the weight of an adult mouse is about fourfold to eight-
fold higher than a neonatal mouse. Therefore, we increased the cell
dose for adult mice to 1 × 107/mouse, which was around fivefold higher
than that for neonatal mice. These mice were analyzed 2 weeks post-
transplantation because we had shown in the preceding section that
the HA-iPSC-ECs/F8 could persist for much longer time in immune-
deficient mice if they were able to survive the first 2 weeks after trans-
plantation (Figure 3). The transplanted cell-Matrigel plugs were easily
identified 2 weeks after the transplantation (Figure 6A). Some of the
cell-matrigel plugs attracted more blood vessels than others. Immuno-
staining of the transplanted cell-Matrigel plugs showed that the GFP-
positive cells also expressed human FVIII and formed a vessel-like net-
work in vivo (Figure 6B).
We collected plasma samples from these mice and from non-
transplanted control F8RG mice. Human FVIII protein was nearly
undetectable (<0.1%) in non-transplanted mouse plasma by ELISA
analysis (Figure 6C). Remarkably, the six of seven mice that received
HA-iPSC1-ECs/F8 had plasma human FVIII protein ranged from
11.2% to 369.2% relative to human plasma standard (Figure 6C). The
severity of HA is clinically classified into severe, moderate and mild,
which is defined as <1%, 1%-5%, and >5%-49% of FVIII activity,
respectively. Thus, our data suggest that the HA-iPSC1-ECs/F8 pro-
duced therapeutic levels of FVIII in HA mice and at least attenuated
severe HA into mild HA.
4 | DISCUSSION
HA is one of the best disease candidates suitable for cell therapy
because correction of the disease only requires a single gene product
that functions outside the cell that had produced it. Therefore, as long
as the potential therapeutic cells can produce and secrete functional
FVIII, engraft well in vivo and are safe, there is no additional functional
requirement for these cells. We showed here that HA patient-derived
iPSCs can be efficiently differentiated into ECs. These ECs can be mod-
ified with lentiviral vectors to produce high levels of functional BDD-
FVIII, comparable to primary human LSECs. These ECs can deliver
therapeutic levels of FVIII to the circulation for the treatment of HA.
Sustained engraftment of therapeutic cells is crucial for the
treatment of HA as well as other genetic diseases. It has been shown
that fetal liver endothelial progenitors have much robust engraft-
ment potential in newborn animals compared with adult LSEC.40,41
We found that, when transplanted at the neonatal stage, the ECs
derived from two different HA-iPSC lines were retained in mice for
at least 16 weeks (Figure 3), suggesting consistent engraftment of
the ECs. When the ECs derived from the same HA-iPSC line were
tested in both neonatal and adult mice, the ECs were retained in all
tested mice but slightly more cells were retained when transplanted
at the neonatal stage (Figure 3). Therefore, our data suggest that the
HA-iPSC-ECs are capable of relatively stable engraftment in mice,
and that transplantation of HA-iPSC-ECs at the neonatal stage is at
least as effective, if not more so, as at the adult stage. Since children
born with HA need to be treated early after birth to prevent poten-
tial bleeding, neonatal cell therapy could be especially beneficial in
the clinical setting.
Based on no increase of the bioluminescence signal upon trans-
plantation, no significant in vivo expansion of the transplanted HA-
iPSC-ECs was evident in neonatal as well as in adult mice in the study
(Figure 3). Consistent with the bioluminescence signal, no teratoma
was detected in any of the mice transplanted with the HA-iPSC-ECs
over 3-4 months. Therefore, the HA-iPSC-ECs were not proliferating
extensively in vivo and not likely tumorigenic. However, the current
study is an initial proof-of-concept study in small animal models. To
completely rule out the tumorigenic potential of the HA-iPSCs and
HA-iPSC-ECs, whole-genome sequencing or deep sequencing for
genes involved in tumorigenesis and a much longer observation time
are necessary in future studies toward clinical applications of these
cells, which is beyond the scope of the current study.
We used lentiviral vectors to express the functional bddF8 gene
in HA-iPSC-ECs at a relatively low MOI of 4 to 8. The transduced HA-
iPSC-ECs secreted FVIII at a level comparable to those by LSECs
in vitro (Figure 2D). We showed previously the activity of this bdd-
FVIII using the same viral vector.42 These transduced HA-iPSC-ECs
produced FVIII after being transplanted into mice by immunostaining
(Figure 4), qRT-PCR (Figure 5), and ELISA (Figure 6). In situ gene
editing of the F8 mutations in HA-iPSCs using transcription activator-
like effector nucleases or clusters of regularly interspaced palindromic
repeats engineered nucleases/Cas-derived RNA-guided endonucle-
ases has now been proven feasible to correct the F8 mutations.43-45
We noticed, however, that the ECs derived from non-diseased iPSCs
expressed around 80-fold less F8 mRNA compared with liver sinusoid
ECs (Figure 1), whereas other tested primary ECs had even lower
expression levels of F8 compared with the health iPSC-ECs (Figure 1).
A new method is needed to specifically differentiate HA-iPSCs into
liver sinusoid ECs, if in situ gene editing approach is used. Most
recently, strategies to express F8 in HA-iPSCs by inserting the func-
tional F8 gene into a safe harbor site or rDNA locus have been
reported.46,47 These ectopic gene expression approaches can ensure
levels of F8 expression. However, the possibilities of random DNA
deletion in the iPSC genome by the gene editing system and the
selection of the p53 pathway inactivated cells48-51 need to be care-
fully addressed before moving forward to clinical trials.
We used two HA mouse models to assess the therapeutic effects
of HA-iPSC-ECs/F8. In immune-competent B6F8 mice that received
immunosuppressive agent cyclosporine A, the transduced HA-iPSC-
ECs significantly reduced the blood loss in a tail-clip assay, when
transplanted at neonatal stage (Figure 5). However, we noticed much
lower number of cells and shorter time of cell retention in the B6F8
mice compared with the immunodeficient NSG mice, suggesting
incompletely immune suppression in these B6F8 mice. We generated
a new immunodeficient mouse stain, F8RG. When HA-iPSC-ECs/F8
were transplanted into F8RG mice, they secreted human FVIII to the
mouse circulation at levels ranged from 11.2% to 369.2% at 2 weeks
post-transplantation. The marked variation on the FVIII levels among
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these mice may be caused by different microenvironments that
impact cell survival and integration of the transplanted cells into the
host vascular system (Figure 6A). Nonetheless, this study provides
proof-of-concept evidence that HA-iPSC-ECs at least attenuate
severe HA to mild HA. In future studies, long-term therapeutic evalua-
tion of HA-iPSC-ECs are needed.
Mouse iPSC-derived ECs had been shown to have therapeutic
effect in HA mice.52 While we were preparing this manuscript, Olgasi
et al reported that HA patient's iPSC-derived ECs transduced with F8
expressing lentivirus produced approximately 6% plasma FVIII when
transplanted via portal vein or intraperitoneally in a different HA
mouse model.53 Hu et al also reported that infusion of the ECs
derived from HA patient's iPSCs that had being gene edited to express
F8 via orbital vein could partially rescue the bleeding phenotype in
HA mice.54 To our knowledge, we are the first group to show the rela-
tively stable engraftment as well as the therapeutic effect of iPSC-
derived ECs at the neonatal stage. Considering the size of a human
body, we think that our subcutaneous transplantation approach allows
transplanting a large number of cells and easy removal of the
transplanted cells if any adverse effects from the transplant are evi-
dent. In future studies, improvement in cell engraftment to reduce cell
loss after transplantation and assessment of the potential long-term
therapeutic cells in animals must be undertaken.
5 | CONCLUSION
ECs can be efficiently generated from HA patients' iPSCs and genetically
modified to express high levels of a functional F8. These HA-iPSC-ECs
are capable of durable engraftment in both neonatal and adult animals,
and they either attenuated or functionally corrected the symptoms of
hemophilia in animal models. Our studies provide proof-of-concept that
HA-iPSC-derived ECs can serve as an autologous cell factory to deliver
FVIII for the treatment of HA in not only adults but also in newborns.
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